Immune checkpoint inhibitors and targeted therapies, two new class of drugs for treatment of metastatic melanoma, have not been compared in randomized controlled trials (RCT). We quantitatively summarized the evidence and compared immune and targeted therapies in terms of both efficacy and toxicity.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jXlAUy
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Abstract Background We have previously published data from 2001 to 2006 showing that adolescent and young adult (AYA) oncology patients ...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
Here is your sample essay on Advertising Advertising is an important element of our culture because it reflects and attempts to change our l...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGQ2DC via IFTTT
-
CXCR4: A New Player in an Old Scene? ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):34-42 Authors: Knopf A, Fritsche MK, Li Y...
-
Abstract Ankylosing spondylitis (AS) is characterized by excessive bone formation with syndesmophytes, leading to bony ankylosis. The cont...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
-
Abstract Purpose To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου